JP2024526060A - 抗ソルチリン抗体の使用方法 - Google Patents

抗ソルチリン抗体の使用方法 Download PDF

Info

Publication number
JP2024526060A
JP2024526060A JP2023575534A JP2023575534A JP2024526060A JP 2024526060 A JP2024526060 A JP 2024526060A JP 2023575534 A JP2023575534 A JP 2023575534A JP 2023575534 A JP2023575534 A JP 2023575534A JP 2024526060 A JP2024526060 A JP 2024526060A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
hvr
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023575534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526060A5 (cg-RX-API-DMAC7.html
Inventor
ポール，ロバート
ジャクソン，サム
リズワン シッディーキー，オメル
エフ． ワード，マイケル
リージア イエ，フェリックス
ワイ． ホアン，ジュリー
ワン，ウィディ
リァオ，イージェ
シー． マンガル，ブライアン
Original Assignee
アレクトル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトル エルエルシー filed Critical アレクトル エルエルシー
Publication of JP2024526060A publication Critical patent/JP2024526060A/ja
Publication of JP2024526060A5 publication Critical patent/JP2024526060A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023575534A 2021-06-08 2022-06-08 抗ソルチリン抗体の使用方法 Withdrawn JP2024526060A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163208238P 2021-06-08 2021-06-08
US63/208,238 2021-06-08
US202163209360P 2021-06-10 2021-06-10
US63/209,360 2021-06-10
US202163225916P 2021-07-26 2021-07-26
US63/225,916 2021-07-26
US202163277069P 2021-11-08 2021-11-08
US63/277,069 2021-11-08
US202263304522P 2022-01-28 2022-01-28
US63/304,522 2022-01-28
US202263311379P 2022-02-17 2022-02-17
US63/311,379 2022-02-17
PCT/US2022/072827 WO2022261648A2 (en) 2021-06-08 2022-06-08 Methods of use of anti-sortilin antibodies

Publications (2)

Publication Number Publication Date
JP2024526060A true JP2024526060A (ja) 2024-07-17
JP2024526060A5 JP2024526060A5 (cg-RX-API-DMAC7.html) 2025-06-16

Family

ID=84426402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575534A Withdrawn JP2024526060A (ja) 2021-06-08 2022-06-08 抗ソルチリン抗体の使用方法

Country Status (6)

Country Link
US (1) US20240132597A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526060A (cg-RX-API-DMAC7.html)
BR (1) BR112023025188A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220428A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022261648A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119679944A (zh) * 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
EP3983441A1 (en) * 2019-06-11 2022-04-20 Alector LLC Anti-sortilin antibodies for use in therapy

Also Published As

Publication number Publication date
EP4351728A4 (en) 2025-08-27
WO2022261648A3 (en) 2023-01-19
EP4351728A2 (en) 2024-04-17
US20240132597A1 (en) 2024-04-25
BR112023025188A2 (pt) 2024-02-27
WO2022261648A2 (en) 2022-12-15
CA3220428A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
JP7564255B2 (ja) 抗ソルチリン抗体及びその使用方法
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
CN115667308A (zh) 抗trem2抗体的使用方法
JP2017511793A (ja) アルツハイマー病治療方法
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
CN118765204A (zh) 抗trem2抗体的使用方法
US20240101681A1 (en) Methods of use of anti-sortilin antibodies
CN117794573A (zh) 抗分拣蛋白抗体的使用方法
CN116964089A (zh) 使用抗分拣蛋白抗体的方法
EA051513B1 (ru) Способы применения антител к сортилину
HK40087465A (zh) 抗trem2抗体的使用方法
HK40099363A (en) Anti-sortilin antibodies and methods of use thereof
HK40028702B (zh) 抗分拣蛋白抗体及其使用方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251205